Latest Market Conditions News

BluGlass Limited has extended its Share Purchase Plan closing date to June 18, 2025, securing an extra $1.5 million in institutional commitments to accelerate production of its gallium nitride lasers.

Polymetals Resources has officially commenced commercial production at its Endeavor silver zinc mine in Cobar, NSW, with zinc concentrate shipments set to begin in early July 2025. The company is progressing steadily toward ramping up output in the second half of the year.

Meridian Energy’s May 2025 report reveals rising hydro storage levels and a dip in national electricity demand, alongside mixed retail sales performance and lower generation prices.

Peet Limited has appointed its long-serving CFO Brett Fullarton as Interim CEO effective immediately, ahead of the planned departure of CEO Brendan Gore on 1 July 2025. This move aims to ensure a smooth leadership transition while a permanent CEO search is underway.

WCM Global Growth Limited has renewed its on-market share buy-back program for 12 months, signaling ongoing confidence in its capital management strategy amid evolving market conditions.

Macarthur Minerals has relaunched a renounceable rights issue to raise nearly A$2 million, fully underwritten by Gold Valley, aiming to fund its Lake Giles Iron Project and strengthen its balance sheet.

Accent Group reports a modest decline in like-for-like sales and margin compression in the second half of FY25, setting full-year EBIT guidance between $108 million and $111 million.

Macquarie Group Limited has announced a quarterly ordinary dividend of AUD 1.7239 per CAP Note security, payable in September 2025, with partial franking and a total distribution rate of 6.84% per annum.

Cochlear Limited has lowered its FY25 earnings guidance due to slower-than-expected sales growth and a sharper decline in Services revenue. Despite this, implant unit growth remains on track, driven by emerging markets.

Nanoveu Limited has locked in a $500,000 funding guarantee through an options underwriting agreement, underpinning its push to commercialise cutting-edge semiconductor and 3D visualisation technologies.

EVE Health Group has launched a $1.5 million capital raise alongside the acquisition of biotech firm Nextract, aiming to expand its footprint in health and pharmaceutical products focused on erectile dysfunction and period pain.

Tower Limited has confirmed Paul Johnston as its permanent CEO after a successful interim period, while initiating a search for a new CFO to sustain its financial leadership.